Newest studies

Association of hearing loss to brain structure and cognition in the Framingham Heart Study

48/100 ✓ Peer-reviewed Long-term cohort studies Alzheimer s & Dementia

Key finding: Midlife hearing loss was associated with smaller brain volumes, accelerated decline in executive function, accelerated accrual of white matter abnormalities, and a near doubling of dementia risk, suggesting a potential causal or biomarker role for midlife hearing loss in the prevention of late‐life dementia. +3 more findings

• Risk Factors
• Brain Scans

Full summary, score breakdown and related studies → Original source

Discovering Hidden Links: Harnessing Similarity Network Fusion to Reveal Common Clusters in Healthy Aging, Mild Cognitive Impairment, and Dementia

36/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: The current study provides evidence that more nuanced, data‐driven approaches can reveal commonalities in the etiology and underlying neurobiology of individuals across traditional categories of CU, MCI, or AD. +4 more findings

• Diagnosis
• Early Stage

Full summary, score breakdown and related studies → Original source

Does Demographic Normalisation Improve the Accuracy of the MoCA and the MMSE for Detecting Mild Cognitive Impairment and Early Dementia ?

33/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: Surprisingly, demographic normalisation worsened rather than improved diagnostic accuracy for detecting MCI with both MoCA and MMSE, reducing their effectiveness as diagnostic tools and confirming our hypothesis. +4 more findings

• Diagnosis
• Early Stage

Full summary, score breakdown and related studies → Original source

Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk

45/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: So far 562 people completed a pre-screening online questionnaire, with 190 passing pre-screening of whom 54% met eligibility criteria. +4 more findings

• Treatments
• Diagnosis
• Clinical Trials

Full summary, score breakdown and related studies → Original source

The relationship between neuroinflammation and clinical features of dementia: An investigation of GFAP levels in Alzheimer's disease and related disorders

38/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: We found significant main effects between GFAP groups and age, diagnosis of AD, diagnosis of VaD, MoCA, sex, CRP and BMI. +4 more findings

• Diagnosis
• Brain Biology
• Biomarkers

Full summary, score breakdown and related studies → Original source

Representing the Cognitive Impairment Continuum of Alzheimer's Disease and Lewy Body Dementia with a Novel Finer‐Scale Cortical Representation via Disease Embedding Tree

42/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: The DET framework has achieved superior performance on the classification task across all the evaluation metrics compared to the traditional machine learning based methods, as demonstrated in Table 1. +3 more findings

Full summary, score breakdown and related studies → Original source

PET and Blood Biomarkers as Predictors of Short‐Term Progression in MCI and Mild Dementia: Prospective Insights from a Southeast Asian Middle‐Income Country

41/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: Among 42 participants (median age: 71 years, 66.7% female), 26 (61.9%) were classified as progressors. +4 more findings

• Biomarkers
• Brain Scans

Full summary, score breakdown and related studies → Original source

Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension

48/100 ✓ Peer-reviewed Treatments The Journal of Prevention of Alzheimer s Disease

Key finding: At 3 years, donanemab slowed disease progression on the Clinical Dementia Rating Scale (CDR)-Sum of Boxes (CDR-SB) in early-start participants versus a weighted ADNI control (-1.2 points; 95 % confidence interval [CI], -1.7, -0.7). +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease

42/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: AcTau174 levels were elevated in all dementia groups compared to controls, with a stepwise increase from controls to MCI-AD (2.2-fold) to AD dementia (3.5-fold, Figure 1). +4 more findings

• Biomarkers
• Diagnosis

Full summary, score breakdown and related studies → Original source

Improving Access to Dementia Care through AI‐Powered Cognitive Rehabilitation Therapy

39/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: In a cohort of 75 patients who completed Moneta's program (average age 73 ± 10, average MoCA score 20 ± 5), 59% had MCI and 33% had dementia. +4 more findings

• Digital Tools
• Treatments

Full summary, score breakdown and related studies → Original source

Community-Based Participatory Research on Art Engagement for People with Dementia in Japan

31/100 ✓ Peer-reviewed Cognitive tests and assessment Innovation in Aging

Key finding: These findings suggest that participatory art, when integrated into community activities, can be a valuable resource for people with dementia and MCI, fostering social participation and self-expression. +1 more finding

• Diagnosis

Full summary, score breakdown and related studies → Original source

Brain Age Gap Predicts Progression to Dementia in SCD and MCI

45/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: 224 subjects progressed to dementia (SCD=38 (9.72%), MCI=186 (50.8%)). +4 more findings

• Early Stage

Full summary, score breakdown and related studies → Original source

A Usability Study of MoCA Solo, a Digital AI‐Assisted Version of the MoCA Test

37/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

Key finding: The MoCA Solo is emerging as a reliable and efficient tool for assessing cognitive impairment in older adults. +2 more findings

• Diagnosis
• Digital Tools

Full summary, score breakdown and related studies → Original source

Association Between Decline in Cognitive Processing Speed and CSF Amyloid‐β 42/40 in Cognitively Healthy Older Adults Aged 70, Followed over 5 to 7 Years: Data from the Gothenburg H70 Birth Cohort Study

51/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: Of the 250 participants, 121 (48.4%) were female and the mean age at follow-up was 76.06 (SD 0.48). +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

AT(N) Biomarkers Across Modalities in the Pathways Between Multimorbidity and Cognition

37/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: After adjusting for age, sex, race/ethnicity, education, APOE ε4, and physical activity, a greater multimorbidity burden (per 3 additional conditions) was associated with worse overall cognition (standardized β =-0.074, 95%CI -0.104 to -0.043) and biomarkers indicative of greater AD pathology, neurodegeneration, and SVD (Figure 1). +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Analytical Qualification of the BD‐Tau Xplorer kit on LUMIPULSE® G1200

38/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: The assay demonstrated robust quantification of BD-Tau in CSF, plasma, and serum with measured concentrations ranging from 3 to 20 pg/mL across 15 paired plasma and serum samples. +4 more findings

Full summary, score breakdown and related studies → Original source

Deep medullary vein abnormalities associated with cognitive function and Alzheimer's disease plasma biomarkers in dementia‐free older adults: The MIND‐China Study

46/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: A higher DMV score was significantly associated with increased likelihoods of MCI (OR=1.19; 95%CI=1.06‒1.34) and amnestic mild cognitive impairment (aMCI) (1.21; 1.06‒1.37), and lower scores in MMSE (-0.01; -0.02‒0.00; p = 0.041), global cognition (-0.05; -0.08‒-0.03), memory (-0.06; -0.10‒-0.02), verbal fluency (-0.05; -0.08‒-0.02), attention (-0.04; -0.07‒-0.01), and executive function (-0.06; -0.10‒-0.03). +2 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Integrative multi‐omics analysis reveals physiological and genetic drivers of CSF biomarker variability: implications in neurodegeneration studies

41/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: We estimated the overall concentration (mean standardized values) and principal components (PCs) of the proteomics and lipidomics data independently. +4 more findings

• Biomarkers
• Genetics

Full summary, score breakdown and related studies → Original source

Aβ positive, tau biomarker negative cognitive impairment is associated with significant non‐Alzheimer's disease neuropathologies

37/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: Cognitive impairment associated with Aβ positivity and low tau (A+T‐) is linked to mixed AD. +2 more findings

• Brain Biology
• Biomarkers

Full summary, score breakdown and related studies → Original source

Association of graph network properties with Alzheimer's pathological hallmarks early in the disease continuum

44/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: We found a positive main effect of CSF Aβ42/40 (p = 0.011) and p-tau181 (p = 0.012) on BC of the Dorsal Attention Network (DAN) (Figure 1). +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Challenges in the identification of underlying pathologies in dementias with predominant behavioral phenotype using laboratory biomarkers

35/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: Neurodegenerative dementias with behavioral clinical presentation are a diverse group of diseases. +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Contribution of genetic and lifestyle factors in resistance‐ and resilience‐related variability in longitudinal pathologic and neurodegeneration trajectory in Dominantly Inherited Alzheimer's Disease

48/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: Subgroups with slower versus faster neurodegeneration, despite similar pathological accumulation, were compared to assess associations with genetic/lifestyles. +3 more findings

• Genetics
• Lifestyle
• Brain Scans

Full summary, score breakdown and related studies → Original source

Neurological and inflammatory biomarkers in CSF along the Alzheimer's Disease spectrum

38/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: For 43 assays, more than 80% of samples provided concentrations within the dynamic range of the assay. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Biomarkers of Underlying Alzheimer Disease Pathology & Neuro-inflammation, But Not Peripheral Inflammation, Predict Disease Clinically-Significant Progression in Mild-Moderate Alzheimer's Disease

39/100 ✓ Peer-reviewed Tau biomarkers Age and Ageing

Key finding: Biomarkers specific to AD pathology (p-tau217, GFAP) rather than peripheral inflammation had robust prognostic value in established AD. +4 more findings

• Biomarkers
• Brain Biology

Full summary, score breakdown and related studies → Original source

Cerebrospinal fluid seed aggregation assay and Alzheimer biomarkers in a Dementia with Lewy Body cohort

39/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: For the 30 clinically-diagnosed DLB participants, 23 (77%) were SAA-positive. +4 more findings

• Biomarkers
• Other Dementias

Full summary, score breakdown and related studies → Original source